CareLit · DOI-Nachweis · Das Gesundheitswesen
Can Routine Data be used to Determine the Target Population of Patients with Type 2 Diabetes in Early Benefit Assessments in Germany?
DOI 10.1055/a-0948-5301
Bibliografische Angaben
Nachweis in CareLit
Autor:innenThoren, C.t.; Schwalm, A.; Mostardt, S.; Weber, D.; Ihle, P.; Altenhofen, L.
ZeitschriftDas Gesundheitswesen
AusgabeS 01/2019
Jahrgang / SeitenJg. 81 · S. S13 bis S19
Kernaussage aus der Literatur
Abstract-Vorschau
Objectives Since 2011, early benefit assessment of all new drugs launched in Germany is mandatory. The exact determination of the appropriate target population (i. e. patients eligible for a drug) plays an important role for subsequent price negotiations. In type 2 diabetes, the size of the target population varies considerably between company dossiers submitted for assessment. Our aim was to explore whether routine…
Zitieren
Zitierempfehlung
Thoren, C.t.; Schwalm, A.; Mostardt, S.; Weber, D.; Ihle, P.; Altenhofen, L (2019) Can Routine Data be used to Determine the Target Population of Patients with Type 2 Diabetes in Early Benefit Assessments in Germany?. Das Gesundheitswesen, 81 (S 01), S13 bis S19. https://doi.org/10.1055/a-0948-5301
Mit CareLit weiterarbeiten